Therapeutic potential of resveratrol for the treatment of type III Gaucher disease
- Author:
Soojin Yoo
;
June-Bum Kim
- Publication Type:Review
- MeSH:
Gaucher Disease
- From:Neurology Asia
2015;20(1):43-48
- CountryMalaysia
- Language:English
-
Abstract:
Gaucher disease is the most common lysosomal storage disorder. Resveratrol is a natural polyphenol
that possesses a wide range of beneficial effects, including anti-inflammatory, anti-oxidant, and
neuroprotective activities. The aim of this study was to determine if resveratrol has a therapeutic
effect on primary fibroblast cells derived from a patient with type III Gaucher disease. 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays were performed to determine
the effect of resveratrol on cell survival. The expression levels of apoptosis-inducing factor (AIF),
Bcl-2-associated X protein (Bax), caspase-3, acetyl-coenzyme A acetyltransferase 1 (ACAT1), E3-
binding protein (E3BP), and citrate synthase (CS) were evaluated by western blotting to characterize
the effect of resveratrol treatment on Gaucher disease cells. Thin-layer chromatography (TLC) was
carried out to measure changes in glucosylceramide levels in resveratrol-treated patient cells. Resveratrol
increased the viability of patient cells compared to that of untreated control cells. Resveratrol treatment
dose-dependently decreased AIF, Bax, and cleaved caspase-3 levels, whereas ACAT1, E3BP, and CS
expression dose-dependently increased. TLC analysis showed reduced levels of glucosylceramides
in resveratrol-treated patient cells. These findings demonstrate that resveratrol can relieve cellular
stress due to glucosylceramide accumulation, and suggest that it should be studied further as a new
therapeutic approach for the treatment of Gaucher disease.
- Full text:P020150623403304618047.pdf
